{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:56:39Z","timestamp":1790268999318,"version":"4.1.0"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Aging"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.neurobiolaging.2018.01.012","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T06:29:55Z","timestamp":1517552995000},"page":"132-139","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Isoprenoids and tau pathology in sporadic Alzheimer's disease"],"prefix":"10.1016","volume":"65","author":[{"given":"Sandra","family":"Pelleieux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Picard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Lamarre-Th\u00e9roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Dea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Leduc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youla S.","family":"Tsantrizos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8018-4545","authenticated-orcid":false,"given":"Judes","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib51","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1074\/jbc.M309888200","article-title":"Human ABCA7 supports apolipoprotein-mediated release of cellular cholesterol and phospholipid to generate high density lipoprotein","volume":"279","author":"Abe-Dohmae","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib1","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/jnc.12654","article-title":"Impaired geranylgeranyl transferase-I regulation reduces membrane-associated Rho protein levels in aged mouse brain","volume":"129","author":"Afshordel","year":"2014","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib2","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1158\/0008-5472.CAN-04-0496","article-title":"Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets","volume":"64","author":"Andersen","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib3","doi-asserted-by":"crossref","first-page":"e1004606","DOI":"10.1371\/journal.pgen.1004606","article-title":"Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias","volume":"10","author":"Beecham","year":"2014","journal-title":"PLoS Genet."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib4","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.11.002","article-title":"Statins, risk of dementia, and cognitive function: Secondary analysis of the Ginkgo Evaluation of Memory Study","volume":"21","author":"Bettermann","year":"2012","journal-title":"J.\u00a0Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib5","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(86)90495-2","article-title":"Alzheimer's disease and tau proteins","volume":"2","author":"Brion","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.nbd.2005.11.007","article-title":"Isoprenoids and Alzheimer's disease: a complex relationship","volume":"22","author":"Cole","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.nbd.2009.05.005","article-title":"Regulation of the brain isoprenoids farnesyl- and geranylgeranyl pyrophosphate is altered in male Alzheimer patients","volume":"35","author":"Eckert","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib9","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib10","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1073\/pnas.83.13.4913","article-title":"Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology","volume":"83","author":"Grundke-Iqbal","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.2008.150433","article-title":"Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study","volume":"80","author":"Haag","year":"2009","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib12","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.neurobiolaging.2011.10.020","article-title":"Pitavastatin decreases tau levels via the inactivation of Rho\/ROCK","volume":"33","author":"Hamano","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","article-title":"Tau phosphorylation: the therapeutic challenge for neurodegenerative disease","volume":"15","author":"Hanger","year":"2009","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00216-008-2306-3","article-title":"Isoprenoid quantitation in human brain tissue: a validated HPLC-fluorescence detection method for endogenous farnesyl- (FPP) and geranylgeranyl pyrophosphate (GGPP)","volume":"392","author":"Hooff","year":"2008","journal-title":"Anal Bioanal. Chem."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12035-012-8285-6","article-title":"Brain isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate are increased in aged mice","volume":"46","author":"Hooff","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib16","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.bbalip.2010.03.014","article-title":"Isoprenoids, small GTPases and Alzheimer's disease","volume":"1801","author":"Hooff","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib52","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12035-013-8627-z","article-title":"Protein prenylation and synaptic plasticity: implications for Alzheimer's disease","volume":"50","author":"Hottman","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/JAD-2010-1203","article-title":"Altered distribution of RhoA in Alzheimer's disease and A\u03b2PP overexpressing mice","volume":"19","author":"Huesa","year":"2010","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib18","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(00)03155-X","article-title":"Statins and the risk of dementia","volume":"356","author":"Jick","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib19","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1001\/archneur.1985.04060100083029","article-title":"Diagnosis of Alzheimer's disease","volume":"42","author":"Khachaturian","year":"1985","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib20","doi-asserted-by":"crossref","first-page":"12479","DOI":"10.1073\/pnas.0403413101","article-title":"A\u00a0tagging-via-substrate technology for detection and proteomics of farnesylated proteins","volume":"101","author":"Kho","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fnmol.2011.00017","article-title":"GSK3 and Alzheimer's disease: facts and fiction","volume":"4","author":"Kremer","year":"2011","journal-title":"Front Mol. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib22","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/ng.2802","article-title":"Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease","volume":"45","author":"Lambert","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib23","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.molmed.2010.07.008","article-title":"APOE and cholesterol homeostasis in Alzheimer's disease","volume":"16","author":"Leduc","year":"2010","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s12031-015-0666-7","article-title":"Effects of rs3846662 variants on HMGCR mRNA and protein levels and on markers of Alzheimer's disease pathology","volume":"58","author":"Leduc","year":"2016","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib25","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/j.1460-9568.2009.06983.x","article-title":"Involvement of paraoxonase 1 genetic variants in Alzheimer's disease neuropathology","volume":"30","author":"Leduc","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib26","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1212\/01.wnl.0000277657.95487.1c","article-title":"Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease","volume":"69","author":"Li","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib28","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jnutbio.2012.07.007","article-title":"Mevalonate-suppressive dietary isoprenoids for bone health","volume":"23","author":"Mo","year":"2012","journal-title":"J.\u00a0Nutr. Biochem."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib29","series-title":"The mevalonate pathway in Alzheimer\u2019s disease - cholesterol and non-sterol isoprenoids, Alzheimer's disease - challenges for the future","author":"Mohamed","year":"2015"},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib53","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nchembio.149","article-title":"Analysis of the eukaryotic prenylome by isoprenoid affinity tagging","volume":"5","author":"Nguyen","year":"2009","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib30","first-page":"S120","article-title":"Cholesterol and tau protein\u2013findings in Alzheimer's and Niemann Pick C's disease","volume":"36 Suppl 2","author":"Ohm","year":"2003","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib31","doi-asserted-by":"crossref","first-page":"26832","DOI":"10.1074\/jbc.M702640200","article-title":"Statins reduce amyloid-beta production through inhibition of protein isoprenylation","volume":"282","author":"Ostrowski","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib32","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fchem.2014.00050","article-title":"Human isoprenoid synthase enzymes as therapeutic targets","volume":"2","author":"Park","year":"2014","journal-title":"Front Chem."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib33","doi-asserted-by":"crossref","first-page":"e8911","DOI":"10.1371\/journal.pone.0008911","article-title":"Light and electron microscopy study of glycogen synthase kinase-3 beta in the mouse brain","volume":"5","author":"Perez-Costas","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1023\/B:BILE.0000019559.84305.47","article-title":"Determination of stable housekeeping genes, differentially regulated target genes and sample integrity: BestKeeper\u2013Excel-based tool using pair-wise correlations","volume":"26","author":"Pfaffl","year":"2004","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib35","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.neurobiolaging.2014.03.037","article-title":"Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease","volume":"35 Suppl 2","author":"Poirier","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11883-012-0307-3","article-title":"Dyslipidemia and the risk of Alzheimer's disease","volume":"15","author":"Reitz","year":"2013","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib37","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3233\/JAD-2006-10408","article-title":"Effect of statins on Alzheimer's disease\u00a0biomarkers in cerebrospinal fluid","volume":"10","author":"Riekse","year":"2006","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-291X(03)00323-1","article-title":"Protein prenylation: a pivotal posttranslational process","volume":"303","author":"Roskoski","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib39","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease","volume":"77","author":"Sano","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib40","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1742-4658.2008.06807.x","article-title":"SREBPs: protein interaction and SREBPs","volume":"276","author":"Sato","year":"2009","journal-title":"FEBS J."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib41","doi-asserted-by":"crossref","first-page":"37046","DOI":"10.1074\/jbc.274.52.37046","article-title":"The neurite retraction induced by lysophosphatidic acid increases Alzheimer's disease-like tau phosphorylation","volume":"274","author":"Sayas","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2990.2007.00846.x","article-title":"Rab6 is increased in Alzheimer's disease brain and correlates with endoplasmic reticulum stress","volume":"33","author":"Scheper","year":"2007","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib43","doi-asserted-by":"crossref","first-page":"92","DOI":"10.5478\/MSL.2011.2.4.092","article-title":"Electrospray-mass Spectrometric analysis of plasma pyrophosphates separated on a multi-modal liquid chromatographic column","volume":"2","author":"Su Hyeon Lee","year":"2011","journal-title":"Mass Spectrom. Lett."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib44","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/hq0901.094500","article-title":"LR11, a mosaic LDL receptor family member, mediates the uptake of ApoE-rich lipoproteins in\u00a0vitro","volume":"21","author":"Taira","year":"2001","journal-title":"Arterioscler Thromb. Vasc. Biol."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib45","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3233\/JAD-2006-9S335","article-title":"GSK-3 is essential in the pathogenesis of Alzheimer's disease","volume":"9","author":"Takashima","year":"2006","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib46","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ab.2008.04.021","article-title":"Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue","volume":"378","author":"Tong","year":"2008","journal-title":"Anal Biochem."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib47","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1002\/jnr.22039","article-title":"Rac1 inhibition negatively regulates transcriptional activity of the amyloid precursor protein gene","volume":"87","author":"Wang","year":"2009","journal-title":"J.\u00a0Neurosci. Res."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib48","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2174\/187152009788451860","article-title":"The intermediate enzymes of isoprenoid metabolism as anticancer targets","volume":"9","author":"Wiemer","year":"2009","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib49","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1741-7015-5-20","article-title":"Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease","volume":"5","author":"Wolozin","year":"2007","journal-title":"BMC Med."},{"key":"10.1016\/j.neurobiolaging.2018.01.012_bib50","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/jnc.12637","article-title":"Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis","volume":"129","author":"Wood","year":"2014","journal-title":"J.\u00a0Neurochem."}],"container-title":["Neurobiology of Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458018300204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0197458018300204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T22:35:16Z","timestamp":1719786916000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0197458018300204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":53,"alternative-id":["S0197458018300204"],"URL":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.01.012","relation":{},"ISSN":["0197-4580"],"issn-type":[{"value":"0197-4580","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isoprenoids and tau pathology in sporadic Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Aging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}